William Jacob Savage - 25 Nov 2024 Form 4 Insider Report for Disc Medicine, Inc. (IRON)

Role
Chief Medical Officer
Signature
By: /s/ Rahul Khara, as Attorney-in-Fact
Issuer symbol
IRON
Transactions as of
25 Nov 2024
Net transactions value
-$756,013
Form type
4
Filing time
26 Nov 2024, 20:03:29 UTC
Previous filing
19 Nov 2024
Next filing
12 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRON Common Stock Options Exercise $51,893 +5,263 +13% $9.86 45,668 25 Nov 2024 Direct F1
transaction IRON Common Stock Options Exercise $120,420 +8,920 +20% $13.50 54,588 25 Nov 2024 Direct F1
transaction IRON Common Stock Sale $567,696 -8,737 -16% $64.98 45,851 25 Nov 2024 Direct F1, F2
transaction IRON Common Stock Sale $233,018 -3,542 -7.7% $65.79 42,309 25 Nov 2024 Direct F1, F3
transaction IRON Common Stock Sale $127,613 -1,904 -4.5% $67.02 40,405 25 Nov 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRON Stock Option (Right to Buy) Options Exercise $0 -5,263 -50% $0.000000 5,258 25 Nov 2024 Common Stock 5,263 $9.86 Direct F1, F5
transaction IRON Stock Option (Right to Buy) Options Exercise $0 -8,920 -23% $0.000000 30,004 25 Nov 2024 Common Stock 8,920 $13.50 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 18, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.44 to $65.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.44 to $66.41, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.44 to $67.32, inclusive.
F5 The shares underlying this option vest in 48 equal monthly installments following July 1, 2021, subject to the Reporting Person's continued service on each such vesting date.
F6 The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.